



“Providing an opportunity for multiple myeloma patients and their loved ones to come together to exchange information for mutual support, comfort, and friendship”

Meeting: Meetings will resume when we are allowed to gather at the address below.  
451 Junction Road  
Madison, WI  
UW West Clinic Room 1287

Enter the clinic... turn left and walk down a short hall...turn left again and conference room 1287 is the last one on the left.

Group Information:

Jayne Schwartz 608- 244-2120  
[schwartzdon@sbcglobal.net](mailto:schwartzdon@sbcglobal.net)

Madison Multiple Myeloma Support Group website  
[madisonmultiplemyeloma.org](http://madisonmultiplemyeloma.org)

Mailing Address: Wisconsin Multiple Myeloma Support Group  
3309 Chicago Avenue Madison, WI 53714-1815

Information Sources :

International Myeloma Foundation (IMF)  
Phone: 800 - 452 - 2873  
Email: [TheIMF@myeloma.org](mailto:TheIMF@myeloma.org)  
Website: [www.myeloma.org](http://www.myeloma.org)

Multiple Myeloma Research Foundation(MMRF)  
Phone: 203 - 972 - 1250  
Email: [info@themmrf.org](mailto:info@themmrf.org)  
Website: [www.multiplemyeloma.org](http://www.multiplemyeloma.org)

Upcoming Meeting Speakers... Mark your calendars now!  
Working on getting a speaker from SHIP (State Health Insurance and Assistance Program) for the August meeting.  
Kell Sidorowic! IM# Regional Director Support & Groups will be our featured speaker in September.  
Marie (allander) UW (arbore) (ancer) (enter) will join us at our October meeting.

Our condolences to the family of Mr. Timothy. Tim passed away April 10, 2020 after a long battle with Myeloma and a recent COVID-19 infection. Tim joined the group February 2015. Don and I saw him often at the UW clinic. When you talked to Tim, he always gave his full attention and shared wisdom without pretense. He was always straightforward and honest with his response. We will miss him at our meetings.

The status of our in-person support group meeting is still undetermined. I have reached out to other support groups that meet at UW facilities to see if they have any information about when and how our meetings might resume. What will they look like moving forward? Will there be limited numbers of people able to attend meetings? Will there be requirements like hand sanitizers, masks, etc.? Will there be a reduction of meeting time? I will keep you updated as I learn more. There is the possibility of a virtual meeting but I don't know that this is what we all need right now.

Your own Natalie Callander (allander) is one of the featured speakers at the Soundable webcast below. Sign up now. This webcast happens Saturday,

Myeloma Crowd Round Table Webcast" May 16, 2020 with Myeloma Experts (2020) "Newly Diagnosed Myeloma" "Delayed Myeloma and 5m Loidosis"  
<https://www.mylomacrowd.org/register-now-for-the-myloma-crowd-3-ma-3-3-interactive-webcast>

Session 1 -- 8:15-10:15 am / Eastern Time 9-11am 3-5:15pm (Central time;<


Topics covered will include managing a new myeloma diagnosis in normal times and during COVID-19 how to choose first lines of therapy and stem cell transplant.

(2020) Updates" Sessions for "Newly Diagnosed and Experienced Patients" => 5 with Myeloma Experts" and HealthTree (2020) Stud Update

The Myeloma Crowd Round Table Webcast on Saturday, May 16 will have updates on the current COVID-19 for myeloma patients, one session to educate newly diagnosed patients, one session to educate experienced patients, and an update on the HealthTree COVID-19 study.

Both sessions will begin with a panel discussion of three experts who will discuss the current state of knowledge of the COVID-19 pandemic and about how it has impacted their myeloma practice and patients.

Each session will include an interactive 65 minute question and answer session for which registered viewers can submit questions via the internet. Registered viewers can choose to participate in either or both sessions if they choose. The final agenda will be sent to registered participants by May 14.



- Natalie Callander, MD, University of Wisconsin-Madison
- Luciano Costa, MD, University of Alabama at Birmingham
- Binod Dhakal, MD, Medical College of Wisconsin

Subcutaneous Daratumumab Receives FDA Approval The US Food and Drug Administration (FDA) approved DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj, or a subcutaneous shot of daratumumab) for the treatment of multiple myeloma patients. This new, fixed-dose formula reduces treatment time from hours to minutes with similar impact as the longer IV administration.

It was approved for both newly diagnosed (transplant ineligible) myeloma patients as well as

- With bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant
- With lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant
- For patients with relapsed or refractory multiple myeloma who have received at least one prior therapy
- With bortezomib and dexamethasone in patients who have received at least 4 one prior therapy
- By itself as a monotherapy
- For patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.

The shot can be administered over 3-5 minutes.

The FDA approval was based on the Phase III COUMBA study, which demonstrated that the subcutaneous version of daratumumab was similar in overall response rate and safety as the intravenous administration. 5s a bonus" this new administration also reduced infusion3related reactions b two3thirds compared to the l2 +ersion 9from 7?@ to -7@<.

DARZALEX FASPRO™ will be available to patients and physicians as soon as the week of May 11, 2020. The intravenous DARZALEX® formulation will also remain available as an option for patients and their physicians.

For financial help using daratumumab, patients can use the Janssen CarePath Program. Through the program, eligible commercial patients pay no more than \$5 per injection, regardless of individual income level. Information on the enrollment process is available online at [www.CarePathSavingsProgram.com/DARZALEX](http://www.CarePathSavingsProgram.com/DARZALEX). For more information, healthcare providers or patients can contact: 1-844-55DARZA (1- 844-553-2792)

International M eloma #oundation 5nnounces #%5 5ppro+al of Sarclisa 9isatu0imab3irfc<

The IMF has a publication on this new approved medication but they are not mailing any yet. Attached is the Tip Card. You can always read the PDF version on their website.

IM# Info Aine B If you or someone you care for has Myeloma, you have questions. Probably, lots of them. You can search the Internet all you want, but other than asking your doctor, there is no better way to get your questions answered than to call the IMF Info Line. Missy, Judy and Paul know their stuff and they want to share what they know with you. Just ask anyone who has called the IMF Info Line. Patients or caregivers are welcome to contact the Info Line staffed by trained specialists at 800-452-CURE (800-452-2873). The Info Line is staffed between 9am and 4pm Pacific Time, 11am to 6pm Central time or [infoline@myeloma.org](mailto:infoline@myeloma.org).

The Trillium Fund was established by our founding support group members to facilitate Multiple Myeloma research here in Madison at the Wisconsin Institute of Medical Research. If you or your family wish to donate or send a memorial to this program, checks can be made payable to the "UW Foundation – Trillium Fund" and sent to UW Carbone Cancer Center, University of Wisconsin Foundation, 1848 University Ave, Madison, WI 53726. Donations may also be made online at [www.supportuw.org/give](http://www.supportuw.org/give) (Trillium Fund in Multiple Myeloma Research – 112903576). For any questions, please call Daniel Rosen at (608) 264-5437 or email [curecancer@supportuw.org](mailto:curecancer@supportuw.org).